NEW YORK (GenomeWeb News) – Nacalai USA today said that it has signed an agreement to distribute Techulon's Glycofect Transfection Reagent platform products in Japan.
The reagents are designed to be particularly effective in primary cells of therapeutic interest, said Nacalai. In addition, the San Diego-based firm said that the Glycofect family of reagents has a unique biodegradable composition that provides for efficacious delivery with very low toxicity in key cell types.